Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Mitotanum [INN-Latin]: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Mitotanum [INN-Latin] - General Information

A derivative of the insecticide dichlorodiphenyldichloroethane that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression. [PubChem]

 

Pharmacology of Mitotanum [INN-Latin]

Mitotanum [INN-Latin] is an oral chemotherapeutic agent indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Mitotanum [INN-Latin] can best be described as an adrenal cytotoxic agent, although it can cause adrenal inhibition, apparently without cellular destruction. The administration of Mitotanum [INN-Latin] alters the extra-adrenal metabolism of cortisol in man; leading to a reduction in measurable 17-hydroxy corticosteroids, even though plasma levels of corticosteroids do not fall. The drug apparently causes increased formation of 6-B-hydroxyl cortisol.

 

Mitotanum [INN-Latin] for patients

PATIENT INFORMATION Follow the links https://www.rxlist.com/cgi/generic2/mitotane_pi.htm https://www.rxlist.com/cgi/generic2/mitotane_wcp.htm https://www.drugs.com/cons/Mitotane.html

 

Mitotanum [INN-Latin] Interactions

Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. In addition, Mitotane should be given with caution to patients receiving other drugs susceptible to the influence of hepatic enzyme induction.

 

Mitotanum [INN-Latin] Contraindications

Mitotane should not be given to individuals who have demonstrated a previous hypersensitivity to it.

 

Additional information about Mitotanum [INN-Latin]

Mitotanum [INN-Latin] Indication: For treatment of inoperable adrenocortical tumours; Cushing's syndrome Mechanism Of Action: Its biochemical mechanism of action is unknown, although data are available to suggest that the drug modifies the peripheral metabolism of steroids as well as directly suppressing the adrenal cortex. Drug Interactions: Anisindione Mitotanum [INN-Latin] decreases the anticoagulant effectAcenocoumarol Mitotanum [INN-Latin] decreases the anticoagulant effectWarfarin Mitotanum [INN-Latin] decreases the anticoagulant effectDicumarol Mitotanum [INN-Latin] decreases the anticoagulant effectSpironolactone Spironolactone antagonizes the effect of mitotane Food Interactions: Not Available Generic Name: Mitotane Synonyms: Not Available Drug Category: Antineoplastic Agents Drug Type: Small Molecule; Approved Other Brand Names containing Mitotane: Chloditan; Chlodithan; Chlodithane; Khlodithan; Lysodren; Mitotan; Mitotanum [INN-Latin]; Absorption: About 40% oral Lysodren is absorbed Toxicity (Overdose): Not Available Protein Binding: 6% Biotransformation: Hepatic and renal Half Life: 18-159 days Dosage Forms of Mitotanum [INN-Latin]: Tablet Oral Chemical IUPAC Name: 1-chloro-4-[2,2-dichloro-1-(2-chlorophenyl)ethyl]benzene Chemical Formula: C14H10Cl4 Mitotane on Wikipedia: https://en.wikipedia.org/wiki/Mitotane Organisms Affected: Humans and other mammals